These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 33464936)

  • 1. Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage.
    Gagnon-Sanschagrin P; Liang Y; Sanon M; Oberdhan D; Guérin A; Cloutier M
    J Med Econ; 2021; 24(1):193-201. PubMed ID: 33464936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
    Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
    J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional variations in prevalence and severity of autosomal dominant polycystic kidney disease in the United States.
    Willey C; Gauthier-Loiselle M; Cloutier M; Shi S; Maitland J; Stellhorn R; Aigbogun MS
    Curr Med Res Opin; 2021 Jul; 37(7):1155-1162. PubMed ID: 33970726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare Resource Utilization and Costs Associated with Autosomal Dominant Polycystic Kidney Disease.
    Blanchette CM; Iorga ŞR; Altan A; Seare JG; Fan Y; Rossetti S; Gutierrez B
    J Health Econ Outcomes Res; 2014; 2(1):63-74. PubMed ID: 37664083
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality risk in patients with autosomal dominant polycystic kidney disease.
    Mladsi D; Zhou X; Mader G; Sanon M; Wang J; Barnett C; Willey C; Seliger S
    BMC Nephrol; 2024 Feb; 25(1):56. PubMed ID: 38365638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The societal economic burden of autosomal dominant polycystic kidney disease in the United States.
    Cloutier M; Manceur AM; Guerin A; Aigbogun MS; Oberdhan D; Gauthier-Loiselle M
    BMC Health Serv Res; 2020 Feb; 20(1):126. PubMed ID: 32070341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010.
    Reule S; Sexton DJ; Solid CA; Chen SC; Collins AJ; Foley RN
    Am J Kidney Dis; 2014 Oct; 64(4):592-9. PubMed ID: 25134777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data.
    Knight T; Schaefer C; Krasa H; Oberdhan D; Chapman A; Perrone RD
    Clinicoecon Outcomes Res; 2015; 7():123-32. PubMed ID: 25759590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiographic Imaging in Autosomal Dominant Polycystic Kidney Disease: A Claims Analysis.
    Sanon Aigbogun M; Stellhorn RA; Pao CS; Seliger SL
    Int J Nephrol Renovasc Dis; 2021; 14():133-142. PubMed ID: 33994802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world costs of autosomal dominant polycystic kidney disease in the Nordics.
    Eriksson D; Karlsson L; Eklund O; Dieperink H; Honkanen E; Melin J; Selvig K; Lundberg J
    BMC Health Serv Res; 2017 Aug; 17(1):560. PubMed ID: 28806944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare resource use and costs associated with chronic kidney disease in US private insurance patients with multiple myeloma.
    Bhowmik D; Song X; Intorcia M; Kent ST; Shi N
    J Oncol Pharm Pract; 2019 Jun; 25(4):855-864. PubMed ID: 29661050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is CAPD a viable option among ADPKD with end stage renal disease population in India? Its outcomes and economics.
    Kaul A; Dharshan R; Bhadhuaria D; Prasad N; Gupta A; Sharma RK
    Saudi J Kidney Dis Transpl; 2015 Sep; 26(5):906-11. PubMed ID: 26354561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure.
    Shaw C; Simms RJ; Pitcher D; Sandford R
    Nephrol Dial Transplant; 2014 Oct; 29(10):1910-8. PubMed ID: 24737444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease.
    Blanchette CM; Liang C; Lubeck DP; Newsome B; Rossetti S; Gu X; Gutierrez B; Lin ND
    Drugs Context; 2015; 4():212275. PubMed ID: 25922609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
    Stein EM; Bonifacio G; Latrémouille-Viau D; Shi S; Guérin A; Wu EQ; Sadek I; Cao X
    J Med Econ; 2021; 24(1):234-243. PubMed ID: 33472483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
    Yu ASL; Shen C; Landsittel DP; Harris PC; Torres VE; Mrug M; Bae KT; Grantham JJ; Rahbari-Oskoui FF; Flessner MF; Bennett WM; Chapman AB;
    Kidney Int; 2018 Mar; 93(3):691-699. PubMed ID: 29290310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-lipoic acid in patients with autosomal dominant polycystic kidney disease.
    Lai S; Petramala L; Muscaritoli M; Cianci R; Mazzaferro S; Mitterhofer AP; Pasquali M; D'Ambrosio V; Carta M; Ansuini M; Ramaccini C; Galani A; Amabile MI; Molfino A; Letizia C
    Nutrition; 2020 Mar; 71():110594. PubMed ID: 31790890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation.
    de Mattos AM; Olyaei AJ; Prather JC; Golconda MS; Barry JM; Norman DJ
    Kidney Int; 2005 Feb; 67(2):714-20. PubMed ID: 15673321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.